Posts

Posted on

MedX Health Corp. Announces Third Quarter 2020 Financial Results and Grant of Stock Options

MedX Health Corp. Announces Third Quarter 2020 Financial Results and Grant of Stock Options

MISSISSAUGA, Ontario–(BUSINESS WIRE)–
MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR (www.sedar.com).

The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of $1,083,772 or $0.01 per share compared with a loss of $577,648, or $0.00 per share for the three months ended September 30, 2019.

The Company reported revenue of $337,885 for the nine months ended September 30, 2020, compared with revenue of $678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy® of $127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of $210,792 for the nine-month period was 63% lower than the $574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of $2,532,171 or $0.02 per share, compared with a loss of $2,086,892, or $0.01 per share for the nine months ended September 30, 2019.

“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy® units to our Brazilian distribution partner, where they will be deployed on our DermSecure® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy® on DermSecure® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”

The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of $0.17 per share, will expire on November 25, 2025, and vest immediately.

MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.

Under the terms of the agreement, MedX will pay Venture North a monthly fee of $6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the “Options”), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of $0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.

Summary of Recent Announcements:

The following is a summary of recent announcements made by the Company, for which further details can be found under the Company’s profile at www.sedar.com.

MedX Announces Sales Agency Agreement with Ziemer Professional Corp.

On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy® on Dermsecure® telemedicine platform across Ontario and Saskatchewan.

MedX Adds Two New Members to Board of Directors

On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services.

MedX Expands Senior Leadership Team

On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlatrous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology.

MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®

On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure® and SIAscopy®. Mike Druhan, who has championed SIAscopy® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.

MedX Announces Closing of Non-Brokered Private Placement

On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of $24,000 were paid.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedX Health Corp

Rob von der Porten

[email protected]

Investor Relations

Bill Mitoulas

[email protected]
Tel: +1.416.479.9547

KEYWORDS: Australia/Oceania Canada New Zealand North America Australia Europe

INDUSTRY KEYWORDS: Medical Devices Health FDA Technology Software Biotechnology

MEDIA:

Logo
Logo
Posted on

Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities

Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities

–    Company has provided more than $3.7 million to COVID-19 response and relief efforts    –

LAKE FOREST, Ill.–(BUSINESS WIRE)–
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has provided $1.2 million in additional funding to U.S and international organizations to support COVID-19 relief efforts, including: The Chicago Community Trust, The Lake County Community Foundation, Silicon Valley Community Foundation,Greater Washington Community Foundation, Americares, ALONE, Family Carers Ireland, Enable Ireland and Toronto Foundation.

Throughout 2020, Horizon has also provided more than $1 million to advocacy organizations to support COVID-19 relief initiatives for people living with rare and rheumatic diseases. This includes educational resources, emergency financial relief and internet connectivity to facilitate continued care via telehealth.

“We recognize that the COVID-19 pandemic is currently impacting more families, communities and organizations than ever before,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “As a global company, we believe it is our fundamental responsibility to support these foundations and organizations so they can thrive and continue to help the communities they serve.”

“While the devastating health and economic crises caused by COVID-19 has disproportionately impacted Chicago’s Black and Latinx communities, we have a once-in-a-generation opportunity to build a more equitable recovery,” said Dr. Helene Gayle, president, chief executive officer, The Chicago Community Trust. “We are grateful for the support of Horizon Therapeutics as we know it’s going to take an unprecedented coalition, across philanthropy, business and communities, to transform the systems that have held back communities of color for centuries.”

“Horizon Therapeutics is among Americares most dedicated partners, consistently providing product donations and annual support that helps us prepare for and respond to emergencies, and fuels our ongoing health programs,” said Christine Squires, president, chief executive officer, Americares. “This donation will allow us to support U.S. safety net clinics as they leverage telehealth technology so patients can access the care they need from home, without worrying about putting themselves or others at risk of COVID-19 infection.”

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

U.S. Media Contact:

Geoff Curtis

Executive Vice President, Corporate Affairs and Chief Communications Officer

[email protected]

Investor Contacts:

Tina Ventura

Senior Vice President, Investor Relations

[email protected]

Ruth Venning

Executive Director, Investor Relations

[email protected]

Ireland Media Contact:

Gordon MRM

Ray Gordon

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Philanthropy Health Foundation General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

UDR Announces 2020 GRESB Score, GRESB Top Performer Status, and Its Winning the 2020 Excellence in Technology Innovation Award by NAA

UDR Announces 2020 GRESB Score, GRESB Top Performer Status, and Its Winning the 2020 Excellence in Technology Innovation Award by NAA

DENVER–(BUSINESS WIRE)–UDR, Inc. (the “Company”) (NYSE: UDR), a leading multifamily real estate investment trust, today announced that it earned a 2020 Global Real Estate Sustainability Benchmark (“GRESB”) survey score of 83 and a GRESB Public Disclosure rating of “A”. With these accomplishments, UDR has been recognized as a GRESB top performer among global real estate firms.

“UDR’s commitment to further developing and accelerating its comprehensive ESG program resulted in an impressive climb within the 2020 GRESB global benchmark,” remarked Dan Winters, GRESB Head of Americas. “With the GRESB benchmark now surpassing 1,200 institutional-quality real estate portfolios globally, UDR’s solid GRESB 4 Star designation places it amongst the global leaders.”

Furthermore, UDR was named the winner of the National Apartment Association (“NAA”) 2020 Excellence in Technology Innovation Award through its installation of state-of-the-art technology at View 34 in Manhattan, New York, to monitor energy consumption and provide granular insight into the performance of the building. The real time insights allow the UDR team to further optimize building systems, enhance operational performance, improve resident comfort, and reduce the Company’s environmental footprint.

“UDR is proud of its leading position in the GRESB survey and being recognized as a technology innovator by NAA,” said Tom Toomey, UDR’s Chairman and CEO. “ESG and technology related initiatives are central to UDR’s strategy, as evidenced by our tangible sustainability goals, innovative and inclusive culture, ongoing commitment to being a strong corporate citizen, and the continued implementation of our Next Generation Operating Platform. Stakeholders continue to emphasize ESG matters, which aligns with our approach of establishing specific, measurable achievement targets while enhancing our efforts in reporting our initiatives and successes. Our 2020 GRESB score is a testament to the significant ESG accomplishments UDR has made and our commitment to the future.”

The GRESB survey evaluates hundreds of real estate companies worldwide in areas such as management, governance, sustainability, environmental and social programs and policies. UDR scored well above the GRESB average in each of the survey’s three main categories which are environmental stewardship, social responsibility, and corporate governance (“ESG”). The Company attained near-maximum scores in both social responsibility and corporate governance. UDR’s overall score of 83 earned a 4 Star designation from GRESB and placed the Company among the top performers within the United States peer group and well above the 2020 GRESB average score of 70.

The GRESB Public Disclosure survey measures material sustainability disclosures of companies. UDR achieved an “A” rating for the second year in a row and had the highest score, 97, within its GRESB-determined comparison group.

Additional details about UDR’s corporate responsibility efforts and goals can be found in the Company’s 2020 Corporate Responsibility Report and on its Corporate Responsibility website.

About UDR, Inc.

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of September 30, 2020, UDR owned or had an ownership position in 51,649 apartment homes including 1,031 homes under development. For over 48 years, UDR has delivered long-term value to shareholders, the best standard of service to Residents and the highest quality experience for Associates.

UDR, Inc.

Trent Trujillo

[email protected]

720-283-6135

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: REIT Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Posted on

Wiley Reimagines Tuition Benefits for Today’s Workforce

Wiley Reimagines Tuition Benefits for Today’s Workforce

Wiley Beyond Takes a Fresh Approach to Tuition Assistance Programs

Aiming to Increase Talent Mobility and Close the Skills Gap for Employees

HOBOKEN, N.J.–(BUSINESS WIRE)–
Wiley Education Services, part of John Wiley and Sons Inc. (NYSE: JWA) (NYSE: JWB), today announced the launch of Wiley Beyond, a new employee benefits solution to help forward-thinking organizations close skills gaps within their organizations and increase talent mobility with the power of learning.

Wiley Beyond provides a platform through which employees can earn degrees or advanced certification, with support from their employer in the form of tuition reimbursement. Wiley Beyond works with employers to execute tuition assistance programs that help attract talent and boost retention, as well as build a more inclusive talent pipeline, remove barriers to talent mobility, and create equitable pathways to development and advancement.

“Today, learning looks much different than a traditional four-year degree, and employers are playing a major role in providing avenues for working adults to pursue higher education – whether through degrees, bootcamps or stackable credentials,” said Todd Zipper, President of Wiley Education Services. “With Wiley Beyond, we are enabling employers to launch better tuition assistance programs that work hard for both the learner’s aspirations and the organization’s needs.”

Wiley Beyond provides a multi-tiered approach to tuition benefits that serves the employer and employee – offering personalized and dedicated support and resources; a user-friendly portal that connects students with potential programs and universities and allows employers to track usage of programs; and a curated network of over 30 learning partners to provide high-quality, low-cost degree and certificate programs.

Wiley will be among the first companies to adopt Wiley Beyond’s tuition benefits solution globally early next year. As the company welcomes the future of work, Wiley will leverage new learning and development capabilities to help colleagues succeed and advance in their careers.

“Learning opportunities are often among the top reasons we find satisfaction in our career,” said Danielle McMahan, Executive Vice President and Chief People Officer, Wiley. “While we explore what the future of work looks like for Wiley colleagues, learning and development tools, like Wiley Beyond, allow us to continue building an agile, empowered colleague culture fueled by the same powerful digital learning content and solutions we offer our customers.”

As COVID-19 changes the future of work, learning solutions, like Wiley Beyond, are important to not only train employees for emerging talent needs, but ensure overall employee retention and satisfaction as well. According to LinkedIn’s 2019 Workforce Learning Report, 94 percent of employees say they would stay at a company longer if it invested in helping them learn.

The launch of Wiley Beyond reinforces Wiley’s mission to bridge the gap from college to career through outcome-driven online education, job training and placement. For more information on Wiley Beyond, please visit beyond.wiley.com.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company’s website can be accessed atwww.wiley.com.

Tag: All Corporate News

Wiley Media Contacts:

Lauren Andrich, +1 201 748 5838, [email protected]

Wiley Investor Contacts:

Brian Campbell, +1 201 748 6874, [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Primary/Secondary Education Communications Continuing Publishing University

MEDIA:

Logo
Logo
Posted on

Box to Present at the Wells Fargo TMT Summit

Box to Present at the Wells Fargo TMT Summit

REDWOOD CITY, Calif.–(BUSINESS WIRE)–
Box, Inc. (NYSE:BOX), a leader in cloud content management, today announced that members of its management team will present at the Wells Fargo TMT Summit on Wednesday, December 2, 2020.

2020 Wells Fargo TMT Summit

Date and Time: December 2, 2020 at 4:00 PM ET

Speakers: Aaron Levie, co-founder and CEO, and Dylan Smith, co-founder and CFO

This event will be webcast live at https://www.box.com/investors and will be available for replay beginning approximately one hour after the live event for ninety (90) days.

About Box

Box (NYSE:BOX) is a leading cloud content management platform that enables organizations to accelerate business processes, power workplace collaboration, and protect their most valuable information, all while working with a best-of-breed enterprise IT stack. Founded in 2005, Box simplifies work for leading organizations globally, including AstraZeneca, General Electric, JLL, and Morgan Stanley. Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. To learn more about Box, visit http://www.box.com. To learn more about how Box powers nonprofits to fulfill their missions, visit Box.org.

Safe Harbor for Forward-Looking Statements

During the course of these events, Box will make forward-looking statements regarding future events or the future financial performance of the company. Statements including words such as “anticipate,” “believe,” “estimate,” or “expect” and statements in the future tense are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual events or actual future results to differ materially from those set forth in the forward-looking statements. Please refer to Box’s latest Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2020 for a discussion of important factors that could cause actual events or actual results to differ materially from those discussed during these events. These forward-looking statements speak only as of the date of the events; Box assumes no obligation, and does not necessarily intend, to update these forward-looking statements.

Investors:

Alice Kousoum Lopatto and Elaine Gaudioso

+1 650-209-3467

[email protected]

Media:

Rachel Levine

+1 650-543-6926

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Security Transport Other Technology Software Internet Data Management Logistics/Supply Chain Management Supply Chain Management Retail

MEDIA:

Logo
Logo
Posted on

Splunk to Present at Upcoming Investor Events

Splunk to Present at Upcoming Investor Events

SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK), provider of the Data-To-Everything Platform, today announced its virtual participation in four upcoming investor events.

  • Tim Tully, chief technology officer, will host a discussion and Q&A session as part of the KeyBanc Capital Markets Cloud Leadership Series beginning at 8:00 a.m. PT on Thursday, December 3, 2020.
  • Doug Merritt, president and CEO, and Jason Child, chief financial officer, will host a discussion and Q&A session at the Credit Suisse 24th Annual Technology Conference beginning at 12:00 p.m. PT on Thursday, December 3, 2020.
  • Doug Merritt and Jason Child will host a discussion and Q&A session at the Raymond James Technology Investors Conference beginning at 12:20 p.m. PT on Monday, December 7, 2020.
  • Jason Child and Tim Tully will host a discussion and Q&A session at the Barclays Global TMT Conference beginning at 9:30 a.m. PT on Thursday, December 10, 2020.

Interested parties may access a webcast of all sessions via the Splunk Investor Relations website at http://investors.splunk.com.

About Splunk Inc.

Splunk Inc. (NASDAQ: SPLK) turns data into doing with the Data-to-Everything Platform. Splunk technology is designed to investigate, monitor, and analyze and act on data at any scale.

Splunk, Splunk>, Data-to-Everything, D2E and Turn Data Into Doing are trademarks and registered trademarks of Splunk Inc. in the United States and other countries. All other brand names, product names, or trademarks belong to their respective owners. © 2020 Splunk Inc. All rights reserved.

Media Contact

Bill Bode

Splunk Inc.

[email protected]

Investor Contact

Ken Tinsley

Splunk Inc.

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Posted on

Agilent Announces Launch of Global Biomarker Pathologist Training Program

Agilent Announces Launch of Global Biomarker Pathologist Training Program

Designed to enrich pathologists’ skills in biomarker interpretation and scoring techniques

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent’s unique expertise in companion diagnostics and partnership with top pharmaceutical companies.

Biomarker testing has profoundly influenced the practice of both pathology and oncology today. Targeted therapies have seen more than 30% increase from 2019, and more than 50% of targeted therapies currently in clinical trials are being co-developed with a predictive biomarker [1][2]. The Agilent Biomarker Pathologist Training Program will enable pathologists to gain confidence with scoring methodologies to enable the pursuit of the right treatment for patients.

“We are excited to successfully launch the Agilent Biomarker Pathologist Training Program to further support our efforts in the fight against cancer,” said Simon Oestergaard, general manager and vice president of Pathology at Agilent. “This program will allow pathologists to learn and practice scoring techniques, to gain the necessary confidence and competence to accurately score biomarker cases in their own laboratories. Combined with Agilent’s high-quality pathology staining solutions this training program will help ensure pathologists can score cases with high concordance.”

The program, which will initially be available in Europe and North America, followed by China and Asia, utilizes a digital platform, Pathcore Scholar, where attendees can navigate both standard and challenging cases. For Agilent products with approved indications, the training, supports Agilent biomarkers only and will provide strategies and best practices for delivering optimal scoring results, which will in turn improve patient outcomes. Training will be offered at different levels, from basic to advanced, and both in-person and remotely, to address individual training requirements.

For more information visit: https://explore.agilent.com/biomarker-training-program

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

References:

  1. Targeted Cancer Therapies

    https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet (accessed May 11, 2020)
  2. Badve, S.; Kumar, G. L., Eds. Predictive Biomarkers in Oncology; Applications in Precision Medicine; Springer: Cham, Switzerland, 2019

 

Catherine Kaye

Agilent Technologies

+44 (0)7775 410632

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Biotechnology Technology Health Pharmaceutical Oncology Research Software Genetics Science Electronic Design Automation

MEDIA:

Logo
Logo
Posted on

Kohl’s Gives $5 Million This Holiday Season to Surprise More Than 100 Nonprofits Who Give with All Their Heart

Kohl’s Gives $5 Million This Holiday Season to Surprise More Than 100 Nonprofits Who Give with All Their Heart

Kohl’s associates across the country nominated local nonprofit organizations that support family health & wellness as part of Kohl’s “A Community with Heart” program

MENOMONEE FALLS, Wis.–(BUSINESS WIRE)–
In the spirit of the holiday season and the company’s ongoing commitment to family health and wellness, Kohl’s (NYSE: KSS) is celebrating families and communities this season by donating $5 million in grants to more than 100 nonprofit organizations across the country that give with all their hearts, not just during the holiday season, but every day of the year. Through Kohl’s A Community with Heart program, Kohl’s associates nationwide nominated and identified local nonprofits that make a difference for families in their communities to be surprised with a grant from Kohl’s. The donations are made possible through Kohl’s philanthropic merchandise program, Kohl’s Cares®, which sells children’s books and toys and donates 100 percent of the net profit to charitable organizations nationwide that improve the health and wellness of families.

“We know that this year has been challenging for so many, including the nonprofit organizations all across the country that serve their local communities, and this holiday season we are honored to be able to celebrate those that give with all their heart,” said Greg Revelle, Kohl’s chief marketing officer. “We’re proud of our Kohl’s associates and their commitment to the communities they serve, and thank them for their many efforts to inspire and empower families by giving back.”

More than 100 nonprofits across 49 states will receive grants ranging from $10,000 to $100,000. Benefiting organizations include local chapters of Alliance for a Healthier Generation, American Cancer Society, American Heart Association, American Red Cross, Boys & Girls Clubs of America, Mental Health America, National Alliance on Mental Health, and National Park Foundation, as well as local hospitals and food banks across the country.

Kohl’s A Community with Heart Map and Surprise Video

Click here to view the full list of grant recipients of Kohl’s A Community with Heart program. Kohl’s associates nationwide joined the fun by surprising local nonprofits to share the good news. To view a video of surprised reactions to receiving a grant from Kohl’s this holiday season, click here.

Kohl’s congratulates the more than 100 grant recipients nationwide, including the following representative groups:

  • American Heart Association Greater Bay Area (Oakland, Calif.) –The American Heart Association Greater Bay Area is on a mission to fight against the number one cause of death in the United States, heart disease, and works to ensure that everyone in California has the opportunity to live a longer, healthier life. With Kohl’s $50,000 grant, the organization will continue combating the effects of COVID-19, as they address core priorities: reducing heart disease risk for women, eliminating tobacco use and vaping, controlling blood pressure, increasing food security, improving mental wellness and resiliency and increasing physical activity—always with a focus on reducing the social and economic barriers to health equity.
  • American Red Cross Greater St. Louis Chapter – The American Red Cross Greater St. Louis Chapter works to prevent and alleviate human suffering in the face of emergencies and educate the community in emergency preparedness, lifesaving First Aid/CPR/AED and water safety. With Kohl’s $85,000 grant, it will enable them to respond to disasters immediately and compassionately, when help and hope are needed most.
  • Boys & Girls Clubs Serving Wake County (Raleigh, N.C.) – Boys & Girls Clubs serves kids in seven neighborhood Clubs across Wake County, with a Teen Center in the heart of Raleigh. The mission of the Clubs, their staff, and volunteers is to ensure every kid, especially those who are most in need, has the greatest opportunity to succeed in school, at work and in life. With Kohl’s $100,000 grant, the Clubs will continue operating at more than twice the normal hours to provide public school students with a safe, reliable place to participate in remote learning. Each day, every child is also offered a snack and a healthy meal, as well as time for after-school fun with sports, arts, crafts, tutoring and more.
  • Gleaners Community Food Bank of Southeastern Michigan (Detroit, Mich.) – Gleaners Community Food Bank of Southeastern Michigan exists to provide households with access to sufficient, nutritious food and resources and works hard to improve the health and well-being of their entire community. Kohl’s $100,000 grant will go a long way, providing critical support for their emergency mobile distributions just launched in March at the beginning of COVID. Given their estimates that 80% of the households accessing food through those mobile distribution sites are families with school-aged children, they plan to continue those well into next year.
  • Jon Bon Jovi Soul Foundation (Philadelphia, Pa.) – The Jon Bon Jovi Soul Foundation has made it their mission to break the cycle of hunger, poverty and homelessness through developing partnerships, creating programs and providing grant funding to support innovative community benefit organizations. With Kohl’s $100,000 grant, the organization plans to continue its work helping individuals and families in need, making an impact in the community through its partnerships and programs.
  • National Alliance on Mental Illness Colorado (Englewood, Colo.) – NAMI Colorado is dedicated to providing advocacy, education, support, and public awareness so that all individuals and families affected by mental illness can build better lives. Kohl’s $75,000 grant will allow the organization to offer the NAMI Peer & Family Support and Education Programs free of cost to Colorado Communities, providing pathways to holistic wellness for those living with mental health challenges and their loved ones who invest their lives as caregivers.

Kohl’s community support extends beyond the A Community with Heart program this holiday season. In lieu of Kohl’s annual Season of Giving drive, Kohl’s is donating $10,000 to three of its existing hometown partners in the Milwaukee area: Penfield Children’s Center, Hunger Task Force and Boys & Girls Clubs of Greater Milwaukee. As part of this initiative, Kohl’s is offering its associates an opportunity to donate to these organizations in Milwaukee to support families in the company’s own backyard.

To learn more about how Kohl’s gives back to communities nationwide, visit Corporate.Kohls.com.

About Kohl’s

Kohl’s (NYSE: KSS) is a leading omnichannel retailer with more than 1,100 stores in 49 states. With a commitment to inspiring and empowering families to lead fulfilled lives, Kohl’s offers amazing national and exclusive brands, incredible savings and an easy shopping experience in our stores, online at Kohls.com and on the Kohl’s mobile app. Since its founding, Kohl’s has given more than $750 million to support communities nationwide, with a focus on family health and wellness. For a list of store locations or to shop online, visit Kohls.com. For more information about Kohl’s impact in the community or how to join our winning team, visit Corporate.Kohls.com or follow @KohlsNews on Twitter.

Julia Fennelly, [email protected], 262.703.1710

KEYWORDS: Pennsylvania Missouri North Carolina Colorado Wisconsin United States North America

INDUSTRY KEYWORDS: Children Primary/Secondary Baby/Maternity Online Retail Education Luxury Other Consumer Discount/Variety Department Stores Women Seniors Religion Pets Mental Health Men Gay & Lesbian Family Home Goods Fitness & Nutrition Consumer Other Retail General Health Health Specialty Fashion Cosmetics Catalog Retail Fund Raising Foundation Philanthropy Other Philanthropy Preschool Teens Other Education Parenting

MEDIA:

Logo
Logo
Posted on

TYME Builds Leadership Team with Announcement of New CEO

TYME Builds Leadership Team with Announcement of New CEO

  • Steve Hoffman, TYME’s Long-Time Chairman and Chief Executive Officer, to Remain Chairman and Chief Science Officer
  • Richie Cunningham, to Succeed Steve Hoffman as Chief Executive Officer

BEDMINSTER, N.J.–(BUSINESS WIRE)–Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company’s Chief Science Officer, after a successful tenure as Chief Executive Officer since 2015. Richie Cunningham, former Icagen CEO and Boehringer Ingelheim executive, has been appointed as TYME’s next Chief Executive Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005214/en/

Richie Cunningham, Chief Executive Officer (Photo: Business Wire)

Richie Cunningham, Chief Executive Officer (Photo: Business Wire)

“We are fortunate to have been able to identify and bring on an individual with Mr. Cunningham’s significant experience in key facets sought by emerging biotech companies. His leadership and expertise in the biopharmaceutical industry, as well as his knowledge of efficient partnering strategies will be invaluable in helping TYME establish itself as a commercial organization with a pipeline of next-generation metabolic-based compounds,” said Steve Hoffman, Chairman and Chief Science Officer of TYME.

Mr. Cunningham brings more than 20 years of successful leadership experience spanning from pre-IND drug discovery through the commercialization and launch of over a dozen therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular and metabolic diseases. Richie brings to TYME an in-depth understanding of maximizing therapeutic lifecycles, enhancing efficiencies and outcomes in biotech business models, and most importantly a commitment to a values-driven culture.

Mr. Cunningham also brings significant experience in mergers & acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales & marketing. Most recently, Richie served as CEO at Icagen, leading the company through two transformational acquisitions, acquiring assets and talent out of Pfizer and Sanofi. While CEO at Icagen, he successfully negotiated and signed multiple licensing deals with Roche, Sanofi and the Cystic Fibrosis Foundation.

Prior to joining Icagen, Mr. Cunningham was an executive with one of the world’s largest pharmaceutical companies, Boehringer Ingelheim, where he held a variety of key strategic and operational roles, including the launch of Boehringer’s first entrance into the oncology market with Gilotrif® (afatinib), an oral tyrosine kinase inhibitor, as a treatment for patients with non-small cell lung cancer.

In addition, Mr. Cunningham excelled in the National Football League holding All-Pro honors for the Dallas Cowboys. His career in the NFL spanned from 1994 until his retirement in 2002.

“TYME is positioned for success and I look forward to working with the leadership team and TYME employees to achieve its strategic short- and long-term objectives. I am excited about the prospects of making a positive impact in the lives of patients and enhancing the value for all stakeholders,” said Richie Cunningham.

About Tyme Technologies

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements/Disclosure Notice

In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates, including SM-88 and TYME- 18, and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical and clinical trials, including the proposed TYME-19 proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” or “anticipates,” and similar words including their use in the negative or by discussions of future matters such as effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and impacts on the Company’s ongoing clinical trials and ability to analyze data from those trials, the cost of development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials, the success of management transitions and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the severity, duration, and economic and operational impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply and the ability to achieve adequate clinical study design and start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trial may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on May 22, 2020, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.

The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

For Investor Relations & Media Inquiries:

Investor Relations

1-212-461-2315

[email protected]

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Photo
Photo
Richie Cunningham, Chief Executive Officer (Photo: Business Wire)
Posted on

Temas Resources Closes $5 Million Institutional Equity Capital

Temas Resources Closes $5 Million Institutional Equity Capital

Temas Resources and Crescita Capital Announce Closing of Major Institutional Backing

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Temas Resources Corp. (“The Company”, “Temas Resources”, CSE: TMAS, OTCQB: TMASF), a publicly traded company focused on the advancement of mineral independence within stable, mining-friendly jurisdictions, announced today it has closed the previously announced institutional funding of $5 million (the “Equity Investment Facility”) from Crescita Capital.

“We are very pleased to be receiving this level of institutional backing so early in the development of Temas Resources’ business plan,” said Michael Dehn, CEO. “With this equity investment Temas Resources’ strategic vision and mission pursuit are being verified by institutional investors.”

The Equity Investment Facility is for an aggregate amount of CAD$5 million and Temas Resources will have three years to utilize the funding to expand and develop its assets. In addition, Temas may use the Equity Investment Facility as security, with the consent of Crescita Capital, to secure additional financing avenues.

“This Equity Investment Facility with Crescita Capital will provide Temas Resources with the capital necessary to allow us to aggressively pursue the exploration and development of Temas Resources properties,” Michael Dehn continued. “This confirmation gives us great confidence in our ability to get the La Blache property through the feasibility stage.”

Temas Resources can draw down funds from the $5 million Equity Investment Facility from time to time during the three year term at Temas Resources’ discretion by providing a notice to Crescita Capital (“Drawdown Notice”), and in return for each Drawdown Notice funded by Crescita Capital, Temas Resources will allot and issue fully paid shares to Crescita Capital (each, a “Private Placement”). The shares issued in connection with any Private Placement will be priced at the higher of (i) the floor price set by Temas Resources and (ii) 90% of the average closing bid price resulting from the following ten days of trading after the Drawdown Notice (“Pricing Period”). The Drawdown Notice amount requested by Temas Resources cannot exceed 700% of the average daily trading volume of the Pricing Period.

The Company paid a 3% commission in shares and issued warrants equal to 8% of the outstanding shares of Temas Resources (together, the “Commitment Fee”), in both cases at the price and on the terms previously announced in our news release dated July 7, 2020.

About Crescita Capital LLC

Crescita Capital is an investment and consultancy group that provides financing and corporate development services for growth-stage companies in markets around the world (https://www.crescitacapital.com).

About Temas Resources

Temas Resources Corp. (“Temas Resources“) (CSE: TMAS) (OTCQB: TMASF) is responding to the growing global demand for iron ore and two strategically important minerals — titanium and vanadium — deemed by the U.S. Department of the Interior as critical to U.S. national security and the economy. Temas Resources’ properties are located in the stable, mining-friendly jurisdiction of Quebec (Canada) bordering Vermont, Maine, and New York State (U.S.) in an area known as the Grenville Geological Province. The Grenville Geological Province is home to Lac Tio, the largest solid ilmenite deposit in the world. As a mineral exploration company focused on the acquisition, exploration and development of iron, titanium, and vanadium properties, Temas Resources has focused its efforts on advancing two major projects in the Grenville Geological Province area. The Company’s first project, the DAB Property, consists of an option for 100% interest on 128 contiguous mineral claims which cover 6,813 hectares (68.14 km²) within the Grenville Geological Province. At the Company’s flagship La Blache Property, the Company has 100% ownership of 48 semi-contiguous mineral claims which cover 2,653 hectares (26.53 km²) within the Grenville Geological Province. All public filings for the Company can be found on the SEDAR website www.sedar.com. For more information about the Company, please visit www.temasresources.com.

On behalf of the Board of Directors of Temas Resources Corp.,

“Kyler Hardy”

Director

Forward Looking Statements

This news release includes certain “Forward‐Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward‐looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward‐looking statements or information. These forward‐looking statements or information relate to, among other things: entry into a definitive agreement for the Equity Investment Facility, closing of the Equity Investment Facility, the Company’s plan to build an advanced base and special metals portfolio, the development of the La Blache Property and the DAB Property, including drilling activities; and future mineral exploration, development and production, the funding of the Company pursuant to the Equity Investment Facility, the issuance of securities pursuant to the Equity Investment Facility, and the resale restrictions and arrangements relating to such securities.

Forward‐looking statements and forward‐looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Temas Resources, future growth potential for Temas Resources and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of iron, titanium, vanadium and other metals; no escalation in the severity of the COVID-19 pandemic; costs of exploration and development; the estimated costs of development of exploration projects; Temas Resources’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

These statements reflect Temas Resources’ respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward‐looking statements or forward-looking information and Temas Resources has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the Company’s dependence on one mineral project; precious metals price volatility; risks associated with the conduct of the Company’s mining activities in Quebec; regulatory, consent or permitting delays; risks relating to reliance on the Company’s management team and outside contractors; risks regarding mineral resources and reserves; the Company’s inability to obtain insurance to cover all risks, on a commercially reasonable basis or at all; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; contests over title to properties, particularly title to undeveloped properties; laws and regulations governing the environment, health and safety; the ability of the communities in which the Company operates to manage and cope with the implications of COVID-19; the economic and financial implications of COVID-19 to the Company; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; the Company’s interactions with surrounding communities and artisanal miners; the Company’s ability to successfully integrate acquired assets; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and the factors identified under the caption “Risk Factors” in Temas Resources’ management discussion and analysis. Readers are cautioned against attributing undue certainty to forward‐looking statements or forward-looking information. Although Temas Resources has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. Temas Resources does not intend, and does not assume any obligation, to update these forward‐looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

Nick Spencer, Investor Relations

Phone: +1 (604) 332-0902

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA: